Zobrazeno 1 - 10
of 271
pro vyhledávání: ''
Autor:
Ashish Panigrahi, Constantine S. Tam, Piers Blombery, Xiangting Chen, John F. Seymour, Dennis A. Carney, Andrew H. Wei, Thomas E Lew, Mary Ann Anderson, Andrew W. Roberts, Ella R. Thompson, David C. S. Huang, Tamia Nguyen, David Westerman, Michael A. Dengler, Victor S Lin, Sasanka M. Handunnetti, Jerry M. Adams
Publikováno v:
Blood. 139:1198-1207
The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). As BCL2 is an important determinant of survival of both myeloid progenitor and B cells, we investigated whether cl
Autor:
Laurence Kraus-Berthier, Lucie Laplane, Véronique Saada, Céline Berthon, Maria E. Figueroa, Bouchra Badaoui, Margaux Sevin, Franck Debeurme, Eric Padron, Thorsten Braun, Qin Yang, Nathalie Droin, Raphael Itzykson, Guido Kroemer, Dorothée Selimoglu-Buet, Eric Solary, Oliver Kepp, Margot Morabito, Alix Derreal, Hannah Newman, Sylvain Thepot, Gabriel Etienne, Miguel Torres-Martin, Sébastien Banquet, Severine Badel, Orianne Wagner-Ballon, Pierre Fenaux
Publikováno v:
Blood
Blood, American Society of Hematology, 2021, 137 (24), pp.3390-3402. ⟨10.1182/blood.2020008729⟩
Blood, American Society of Hematology, 2021, 137 (24), pp.3390-3402. ⟨10.1182/blood.2020008729⟩
Mouse models of chronic myeloid malignancies suggest that targeting mature cells of the malignant clone disrupts feedback loops that promote disease expansion. Here, we show that in chronic myelomonocytic leukemia (CMML), monocytes that accumulate in
Autor:
Hsin-An Hou, Amy L. Aldrich, Amy F McLemore, Susan Geyer, Eric Padron, Kathy L. McGraw, Abhishek Dhawan, Rami S. Komrokji, Sarah Warren, John L. Cleveland, Kyle J. MacBeth, Steffen Boettcher, Alan F. List, Benjamin L. Ebert, Amy Sullivan, Jeffrey E. Lancet, Erika A. Eksioglu, Manja Meggendorfer, Najla Al Ali, Torsten Haferlach, David A. Sallman
Publikováno v:
Blood. 136:2812-2823
Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis. The pre
Autor:
Xose S. Puente, Ana Muntañola, Ander Diaz-Navarro, José I. Martín-Subero, Blanca Espinet, Roser Vilarrasa-Blasi, Guillem Clot, Cristina López, Marta Kulis, Ferran Nadeu, Rafael Valdés-Mas, Vicente Chapaprieta, Marta Aymerich, Dolors Costa, Elias Campo, David Torrents, Sílvia Beà, Jesús Gutiérrez-Abril, Armando López-Guillermo, David Martín-García, Pedro Jares, Ralf Küppers, Eva Giné, Inmaculada Ribera-Cortada, Montserrat Puiggròs, Giancarlo Castellano, Dolors Colomer, Romina Royo, Martí Duran-Ferrer, Alba Navarro, Reiner Siebert
Publikováno v:
Blood. 136:1419-1432
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm initially driven by CCND1 rearrangement with 2 molecular subtypes, conventional MCL (cMCL) and leukemic non-nodal MCL (nnMCL), that differ in their clinicobiological behavior. To identify the gen
Autor:
Nathan Fowler
Publikováno v:
Blood
Intolerance is the most common reason for kinase inhibitor (KI) discontinuation in chronic lymphocytic leukemia (CLL). Umbralisib, a novel highly selective phosphatidylinositol 3-kinase δ (PI3Kδ)/CK1ε inhibitor, is active and well tolerated in CLL
Autor:
Sriram Balasubramanian, Quratulain Qureshi, Christopher Rushton, Miguel Alcaide, Nicole Thomas, Krysta M. Coyle, Bruno M. Grande, Prasath Pararajalingam, Barbara Meissner, Joseph M. Connors, Diego Villa, Ryan D. Morin, Constantine S. Tam, Randy D. Gascoyne, David W. Scott, Graham W. Slack, Christian Steidl, Nathalie A. Johnson, Timothy E. Audas, Marco A. Marra, Sarah E. Arthur, Rishu Agarwal, Andrew J. Mungall, Merrill Boyle, Sarah-Jane Dawson, Georg Lenz
Publikováno v:
Blood. 136:572-584
Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma (NHL) that is incurable with standard therapies. The genetic drivers of this cancer have not been firmly established, and the features that contribute to differences in clinical co
Autor:
Peter Vandenberghe, Daan Dierickx, Lukas Marcelis, Thomas Tousseyn, G Ameye, Koen Debackere, Jo-Anne van der Krogt, Carlos Graux, Jan Cools, Lucienne Michaux, Katrien Van Roosbroeck, Iwona Wlodarska, Julio Finalet Ferreiro
Publikováno v:
Blood, Vol. 135, no. 8, p. 584-588 (2020)
TO THE EDITOR: Follicular T-cell lymphoma (FTCL) is a rare nodal mature T-cell neoplasm included in a broader category of angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of T follicular helper (TFH) cell origin by the 2017 World H
Autor:
Oscar Silva, Philip L. Bulterys
Publikováno v:
Blood. 137(24)
Autor:
Mario Cazzola, Alessandro M. Vannucchi, Chiara Paoli, Rossella Manfredini, Paola Guglielmelli, Elisa Rumi, Francesco Mannelli, Annalisa Pacilli, Sara Fiaccabrino, Giada Rotunno, Giada Brogi, Giovanni Barosi, Benedetta Sordi, Francesca Gesullo, Carmela Mannarelli, Ilaria M. Marone
Publikováno v:
Blood. 133:2802-2808
TO THE EDITOR: The discovery of prognostically informative mutations in patients with primary myelofibrosis (PMF)[1][1] prompted the development of mutation-enhanced risk scores.[2][2][⇓][3][⇓][4][⇓][5]-[6][6] Among these mutations, those in AS
Autor:
Mathijs A. Sanders, Sandra Kaiser, Wei Wang, Sarolta Bojtine Kovacs, Lars Bullinger, Bruno Cassinat, Annelieke Zeilemaker, Christoph Koellerer, Peter J. M. Valk, Jonas S. Jutzi, Titiksha Basu, Adil Al Hinai, Jenny Ostendorp, Brigitte Schlegelberger, Heike L. Pahl, Emmanuel Raffoux, Doris Steinemann, Maximilian Pellmann, Konrad Aumann
Publikováno v:
Blood, 133(16), 1766-1777. American Society of Hematology
In acute myeloid leukemia (AML), acquired genetic aberrations carry prognostic implications and guide therapeutic decisions. Clinical algorithms have been improved by the incorporation of novel aberrations. Here, we report the presence and functional